BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 17057389)

  • 1. Prospective controlled cohort studies on long-term therapy of breast cancer patients with a mistletoe preparation (Iscador).
    Grossarth-Maticek R; Ziegler R
    Forsch Komplementmed; 2006 Oct; 13(5):285-92. PubMed ID: 17057389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised and non-randomised prospective controlled cohort studies in matched-pair design for the long-term therapy of breast cancer patients with a mistletoe preparation (Iscador): a re-analysis.
    Grossarth-Maticek R; Ziegler R
    Eur J Med Res; 2006 Nov; 11(11):485-95. PubMed ID: 17182361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective controlled cohort studies on long-term therapy of cervical cancer patients with a mistletoe preparation (Iscador).
    Grossarth-Maticek R; Ziegler R
    Forsch Komplementmed; 2007 Jun; 14(3):140-7. PubMed ID: 17596694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective controlled cohort studies on long-term therapy of ovairian cancer patients with mistletoe (Viscum album L.) extracts iscador.
    Grossarth-Maticek R; Ziegler R
    Arzneimittelforschung; 2007; 57(10):665-78. PubMed ID: 18074761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized and non-randomized prospective controlled cohort studies in matched pair design for the long-term therapy of corpus uteri cancer patients with a mistletoe preparation (Iscador).
    Grossarth-Maticek R; Ziegler R
    Eur J Med Res; 2008 Mar; 13(3):107-20. PubMed ID: 18499556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study.
    Grossarth-Maticek R; Kiene H; Baumgartner SM; Ziegler R
    Altern Ther Health Med; 2001; 7(3):57-66, 68-72, 74-6 passim. PubMed ID: 11347286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrolective, comparative, epidemiological cohort study with parallel groups design for evaluation of efficacy and safety of drugs with "well-established use".
    Bock PR; Friedel WE; Hanisch J; Karasmann M; Schneider B
    Forsch Komplementarmed Klass Naturheilkd; 2004 Aug; 11 Suppl 1():23-9. PubMed ID: 15353899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individual Patient Data Meta-analysis of Survival and Psychosomatic Self-regulation from Published Prospective Controlled Cohort Studies for Long-term Therapy of Breast Cancer Patients with a Mistletoe Preparation (Iscador).
    Ziegler R; Grossarth-Maticek R
    Evid Based Complement Alternat Med; 2010 Jun; 7(2):157-66. PubMed ID: 18955332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland].
    Bock PR; Friedel WE; Hanisch J; Karasmann M; Schneider B
    Arzneimittelforschung; 2004; 54(8):456-66. PubMed ID: 15460213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival of cancer patients treated with mistletoe extract (Iscador): a systematic literature review.
    Ostermann T; Raak C; Büssing A
    BMC Cancer; 2009 Dec; 9():451. PubMed ID: 20021637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland.
    Augustin M; Bock PR; Hanisch J; Karasmann M; Schneider B
    Arzneimittelforschung; 2005; 55(1):38-49. PubMed ID: 15727163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mistletoe as complementary treatment in patients with advanced non-small-cell lung cancer treated with carboplatin-based combinations: a randomised phase II study.
    Bar-Sela G; Wollner M; Hammer L; Agbarya A; Dudnik E; Haim N
    Eur J Cancer; 2013 Mar; 49(5):1058-64. PubMed ID: 23218588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Problems of randomized studies in complementary medicine demonstrated in a study on mistletoe treatment of patients with breast cancer].
    Gerhard I; Abel U; Loewe-Mesch A; Huppmann S; Kuehn JJ
    Forsch Komplementarmed Klass Naturheilkd; 2004 Jun; 11(3):150-7. PubMed ID: 15249749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting inflammation in cancer-related-fatigue: a rationale for mistletoe therapy as supportive care in colorectal cancer patients.
    Bock PR; Hanisch J; Matthes H; Zänker KS
    Inflamm Allergy Drug Targets; 2014; 13(2):105-11. PubMed ID: 24766319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complementary Treatment with Mistletoe Extracts During Chemotherapy: Safety, Neutropenia, Fever, and Quality of Life Assessed in a Randomized Study.
    Pelzer F; Tröger W; Nat DR
    J Altern Complement Med; 2018; 24(9-10):954-961. PubMed ID: 30247950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of tumor growth stimulation in a panel of 16 human tumor cell lines by mistletoe extracts in vitro.
    Maier G; Fiebig HH
    Anticancer Drugs; 2002 Apr; 13(4):373-9. PubMed ID: 11984083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticarcinogenic and antimetastatic activity of Iscador.
    Kuttan G; Menon LG; Antony S; Kuttan R
    Anticancer Drugs; 1997 Apr; 8 Suppl 1():S15-6. PubMed ID: 9179361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pleura carcinosis. Cytomorphological findings with the mistletoe preparation iscador and other pharmaceuticals.
    Salzer G
    Oncology; 1986; 43 Suppl 1():66-70. PubMed ID: 3808576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression profiles of different breast cancer cells compared with their responsiveness to fermented mistletoe (Viscum album L.) extracts Iscador from oak (Quercus), pine (Pinus), white fir (Abies) and apple tree (Malus) in vitro.
    Eggenschwiler J; Patrignani A; Wagner U; Rehrauer H; Schlapbach R; Rist L; Ramos MH; Viviani A
    Arzneimittelforschung; 2006 Jun; 56(6A):483-96. PubMed ID: 16927530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients are talking about ... Iscador (mistletoe).
    Decker G
    Clin J Oncol Nurs; 2001; 5(4):183-4. PubMed ID: 12690624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.